Dexamethasone Treatment Options in United Kingdom (Updated 8/25)

Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

NCT01554852

Unknown

The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib. Patients who do not have the best response to their initial treatment may then also be given a combination of cyclophosphamide, dexamethasone plus bortezomib. Patients who are relatively fit may, on their doctor's advice, go on to receive more intensive chemotherapy, sup... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/07/2018

Locations: 112 sites UK wide, United Kingdom, Not set

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

NCT03562169

Recruiting

Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase). Primary Objectives The primary objectives of this study are to determine: * The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of a proteasome inhibitor * The influence of a consolidation and maintenance strategy on the Durability of Response (DuR:PFS) Secondary objectives The sec... Read More

Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase). Primary Objectives The primary objectives of this study are to determine: * The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of a proteasome inhibitor * The influence of a consolidation and maintenance strategy on the Durability of Response (DuR:PFS) Secondary objectives The secondary objectives of this study are to determine: * Overall survival * Time to disease progression * The overall response rate following ixazomib, thalidomide and dexamethasone (ITD) re-induction * Time to next treatment * Progression-free survival 2 (PFS2) * Duration of response * Minimal Residual Disease (MRD) negative rate post re-induction, post-ASCT and conversion after ITD consolidation * Engraftment kinetics * Toxicity and safety * Quality of life (QoL) Participant population (refer to protocol section 9 for a full list of eligibility criteria). * Relapsed MM (with measurable disease by IMWG criteria) previously treated with ASCT * First progressive disease (PD) at least 12 months since first ASCT, requiring therapy. * ECOG Performance Status 0-2 * Aged at least 18 years * Adequate full blood count and renal, hepatobiliary, pulmonary and cardiac function * Written informed consent Interventions: All participants will be registered at trial entry and will receive re-induction therapy with 4-6, 28-day cycles of ixazomib, thalidomide and dexamethasone (ITD), in order to reach maximum response. Participants who achieve at least stable disease (SD) will be randomised on a 1:1 basis to receive either conventional ASCT (ASCTCon), using melphalan, or augmented ASCT (ASCTAug), using melphalan with ixazomib. All participants achieving or maintaining a minimal response (MR) or better following trial ASCT will undergo a second randomisation to consolidation and maintenance or no further treatment. Participants randomised to consolidation and maintenance will receive treatment as follows: consolidation with 2 cycles of ITD and maintenance with ixazomib until disease progression. Number of participants: 406 participants will be registered into the trial to allow 284 participants to be randomised at the first randomisation (R1) and 248 participants to be randomised at the second randomisation (R2). Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/07/2018

Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +90 locations

Aberdeen Royal Infirmary, Aberdeen, Not set

Monklands Hospital, Airdrie, Not set

University Hospital Ayr, Ayr, Not set

Barnsley Hospital, Barnsley, Not set

Basingstoke & North Hampshire Hospital, Basingstoke, Not set

Royal United Hospital, Bath, Not set

Good Hope Hospital, Birmingham, Not set

Heartlands Hospital, Birmingham, Not set

Queen Elizabeth Hospital, Birmingham, Not set

Blackpool Victoria Hospital, Blackpool, Not set

Pilgrim Hospital, Boston, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Bradford Royal Infirmary, Bradford, Not set

Bristol Haematology & Oncology Centre, Bristol, Not set

Southmead Hospital, Bristol, Not set

Queen's Hospital, Burton Upon Trent, Not set

Addenbrooke's Hospital, Cambridge, Not set

St Helier Hospital, Carshalton, Not set

Cheltenham General Hospial, Cheltenham, Not set

Chesterfield Royal Hospital, Chesterfield, Not set

Countess of Chester Hospital, Chester, Not set

St Richards Hospital, Chichester, Not set

University Hospital Coventry, Coventry, Not set

Royal Derby Hospital, Derby, Not set

Dewsbury Hospital, Dewsbury, Not set

Russells Hall Hospital, Dudley, Not set

Ninewells Hospital, Dundee, Not set

Hairmyres Hospital, East Kilbride, Not set

Western General Hospital, Edinburgh, Not set

Beatson Cancer Centre, Glasgow, Not set

New Victoria Hospital, Glasgow, Not set

Gloucestershire Royal Hospital, Gloucester, Not set

Grantham and District Hospital, Grantham, Not set

Diana Princess of Wales Hospital, Grimsby, Not set

Calderdale Royal Hospital, Halifax, Not set

Harrogate District Hospital, Harrogate, Not set

Huddersfield Royal Infirmary, Huddersfield, Not set

Castle Hill Hospital, Hull, Not set

Raigmore Hospital, Inverness, Not set

Ipswich Hospital, Ipswich, Not set

Kidderminster Hospital, Kidderminster, Not set

University Hospital Crosshouse, Kilmarnock, Not set

St James's University Hospital, Leeds, Not set

Leicester Royal Infirmary, Leicester, Not set

Lincoln County Hospital, Lincoln, Not set

Royal Liverpool University Hospital, Liverpool, Not set

University Hospital Aintree, Liverpool, Not set

Guys and St Thomas's Hospital, London, Not set

Kings College Hospital, London, Not set

Royal Marsden Hospital, London, Not set

St Barts Hospital, London, Not set

University College London Hospital, London, Not set

Maidstone Hospital, Maidstone, Not set

Manchester Royal Infirmary, Manchester, Not set

The Christie, Manchester, Not set

Borders General Hospital, Melrose, Not set

James Cook University Hospital, Middlesbrough, Not set

Milton Keynes General Hospital, Milton Keynes, Not set

Freeman Hospital, Newcastle, Not set

North Tyneside General Hospital, North Shields, Not set

Norfolk & Norwich University Hospital, Norwich, Not set

Nottingham City Hospital, Nottingham, Not set

Royal Oldham Hospital, Oldham, Not set

Churchill Hospital, Oxford, Not set

Royal Alexandra Hospital, Paisley, Not set

Derriford Hospital, Plymouth, Not set

Pontefract Hospital, Pontefract, Not set

Whiston Hospital, Prescot, Not set

Royal Berkshire Hospital, Reading, Not set

Redditch Hospital, Redditch, Not set

Salford Royal Hospital, Salford, Not set

Salisbury Hospital, Salisbury, Not set

Scunthorpe General Hospital, Scunthorpe, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

St Helens Hospital, St Helens, Not set

Stafford County Hospital, Stafford, Not set

Stepping Hill Hospital, Stockport, Not set

Royal Stoke University Hospital, Stoke-on-Trent, Not set

Sunderland Royal Hospital, Sunderland, Not set

King's Mill Hospital, Sutton In Ashfield, Not set

Singleton Hospital, Swansea, Not set

Musgrove Park Hospital, Taunton, Not set

St George's Hospital, Tooting, Not set

Tunbridge Wells Hospital, Tunbridge Wells, Not set

Pinderfields General Hospital, Wakefield, Not set

Royal Hampshire County Hospital, Winchester, Not set

Wishaw Hospital, Wishaw, Not set

New Cross Hospital, Wolverhampton, Not set

Worcestershire Royal Hospital, Worcester, Not set

Worthing Hospital, Worthing, Not set

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.

NCT02121197

Completed

To review the safety and efficacy of injections with Ozurdex (700 μg dexamethasone) in clinical practice management of patients with DME.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/17/2018

Locations: Department of Ophthalmology, Kuopio University Hospital, Kuopio, Not set +24 locations

Department of Ophthalmology, Kuopio University Hospital, Kuopio, Not set

Department of Ophthalmology, Centre Hospitalier Henri Duffaut,, Avignon, Not set

Department of Ophthalmology, Croix Rousse University Hospital, Lyon, Not set

Clinical Trial Unit, Department of Ophthalmology, CHU Nord, Aix Marseille University, Marseille, Not set

Coscas Eye Clinic, Paris, Not set

Department of Ophthalmology Lariboisière Hospital, Paris, Not set

Ophthalmology Department, Kaplan Medical Center, Rehovot, Not set

Department of Ophthalmology Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Ophthalmic Research Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, Bari, Not set

Excellence Eye Research Centre University G. d'Annunzio of Chieti-Pescara, Chieti, Not set

Department of Ophthalmology University Vita Salute - Scientific Institute of San Raffael, Milan, Not set

Centre for Clinical Trials, Department of Ophthalmology University of Padova, Padova, Not set

G.B.Bietti Eye Foundation - IRCCS, Rome, Not set

Department of Ophthalmology University of Udine, Udine, Not set

Center for Clinical Trials - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Not set

Instituto de Retina e Diabetes Ocular de Lisboa (IRL), Lisboa, Not set

Ophthalmology Department, Dos de Maig Hospital, Barcelona, Not set

Hospital Vall d'Hebrón Department of Ophthalmology, Barcelona, Not set

Instituto de Microcirugia Ocular, Barcelona, Not set

Vallés Oftalmologia Research, Barcelona, Not set

Ophthalmology Department, Hospital de LaPaz, Madrid, Not set

Servicio de Oftalmologia, Hospital Universitario Y Politecnico de la Fe, Valencia, Not set

Retinal Clinic, St Eriks Hospital, Stockholm, Not set

Ophthalmology Clinical Trials Unit Frimley Park Hospital Foundation Trust, Frimley, Not set

NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust, London, Not set

Conditions: Diabetic Macular Edema

Register for Updates

Learn More ›

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

NCT02280993

Unknown

To combine Brentuximab Vedotin with Dexamethasone, AraC and Cisplatin (DHAP) chemotherapy in patients with Hodgkin lymphoma (HL) refractory to first line chemotherapy or in first relapse is expected to induce a significantly higher (metabolic) complete remission (CR) rate prior to consolidation with BEAM, as judged by FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose)-PET negativity. This will be compared with published data on DHAP salvage only. Increasing the metabolic CR rate prior to co... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/12/2018

Locations: Rigshospitalet, Copenhagen, Not set +12 locations

Conditions: Hodgkin Lymphoma, Refractory, Relapse

Register for Updates

Learn More ›

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

NCT00424047

Completed

To compare the efficacy of oral CC-5013 in combination with oral pulse high-dose dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for subjects with relapsed or refractory multiple myeloma."

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/18/2017

Locations: Royal Prince Alfred Hospital, Camperdown, New South Wales +68 locations

Royal Prince Alfred Hospital, Camperdown, New South Wales

Peter MacCallum Cancer Centre Divsion of Haematology/Medical Oncology, East Melbourne, Victoria

The Alfred Hospital, Prahran, Victoria

Border Medical Oncology, Wodonga, Victoria

Box Hill Hospital, Box Hill, Not set

Frankston Hospital Oncology Research, Frankston, Not set

Royal Brisbane Hospital, Herston, Not set

The Royal Melbourne Hospital, Parkville, Not set

Mater Public Hospital, South Brisbane, Not set

University Hospital of Salzburg St Johanns Spital, Salzburg, Not set

Wilhelminenspital, Vienna, Not set

CHU Saint-Luc, Brussel, Not set

UZ Gasthuisberg, Leuven, Not set

Centre Hospitalier Lyon Sud, Chemin Grand Revoyet, Not set

Hopital Claude Huriez, Lille, Not set

Centre Hospitalier Hotel-Dieu, Nantes, Not set

Hopital Saint-Loius, Paris, Not set

Chu de Bordeaux Groupe Hospitalier Sud, Pessac, Not set

CHU Purpan, Toulouse cedex 9, Not set

CHU Nancy - Hopital Brabois, Vandoeuvre, Not set

Universitaetsklinikum Charite, Berlin, Not set

Universitatsklinik ChariteMedizinische Fakultaet der HumboldtUniversitaet zu Berlin, Berlin, Not set

Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Dusseldorf, Not set

Universitaetsklinkum Erlangen, Erlangen, Not set

Klininkum der Johann-Wolfgang-Goethe-Universtat, Frankfurt am Main, Not set

Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V, Heidelberg, Not set

Universitatsklinik Muenster Medizinische Klinik A, Muenster, Not set

Klinikum der Univeristact Muenchen, Munchen, Not set

Universitaetsklinikum Tuebingen, Tubingen, Not set

"Alexandras" General Hospital of Athens, Athens, Not set

University Hospital GalwayHaematology Department, Galway, Co. Galway

Belfast City HospitalHaematology Department, Belfast, Not set

Hope Directorate Haematology Oncology Service St. James Hospital, Dublin 8, Not set

MidWestern Regional Hospital, Limerick, Not set

Rambam Medical Center, Haifa, Not set

Hadassah University Hospital, Jerusalem, Not set

Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Not set

The Chaim Sheba Medical Center, Tel Hashomer, Not set

Policlinico Sant'Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliera San Martino, Genova, Not set

Ospedale Niguarda Ca Granda, Milano, Not set

Policlinico San Matteo, Pavia, Not set

Univerita La Sapien, Roma, Not set

Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Torio, Not set

Policlinico Universitario a Gesttione diretta di Udine, Udine, Not set

Institute of Internal Diseases University of Medicine, Gdansk, Not set

University School of Medicine, Lublin, Not set

Institute of Haematology and Blood Transfusion, Warsaw, Not set

Hospital Clinic, Barcelona, Not set

Hospital Universitario de la Princessa, Madrid, Not set

Hospital Doce de Octubre, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universtario Marques de Valdecilla, Santander, Not set

Sahlgrenska University Hospital Department of Hematology and Coagulation, Goteborg, Not set

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Not set

Kantonsspital St. Gallen, St. Gallen, Not set

Universitätsspital Zürich, Zürich, Not set

Cherkassy Regional Oncology Center, Cherkassy, Not set

Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Not set

Kiev Bone Marrow Transplantation Center Bone Marrow Department, Kiev, Not set

Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Not set

Institute of Blood Pathology and Transfusion Medicine of the UAMS, Lviv, Not set

Institute of Blood Pathology and Transfusion Medicine of the UAMS Hematology Department, Lvov, Not set

Odess Regional Clinical Hospital, Odessa, Not set

Zhitomir Regional Clinical Hospital, Zhitomir, Not set

University College Hospital Trust, London, Bloomsbury

Bristol Haematology and Oncology Centre, Bristol, Not set

Haematology Dept, 4th Floor Thomas Guy House, London, Not set

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone

NCT01892163

Completed

Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical coherence tomography (OCT)-guided PRN dosing in patients with refractory diabetic macular edema.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/03/2017

Locations: Moorfields Eye Hospital NHS Foundation trust, London, Not set

Conditions: Diabetic Macular Edema

Register for Updates

Learn More ›

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)

NCT01459211

Completed

The purpose of this study is to establish the safety and efficacy of a combination of dexamethasone and lenalidomide (Revlimid®) (D+L) in subjects with relapsed or refractory CLL who have failed or are unable to tolerate standard up-front therapy with regimens containing Fludarabine or in those with mutations in the p53 gene, CAMPATH-1H.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/07/2016

Locations: Royal Liverpool University Hospital, Liverpool, Not set +1 locations

Conditions: Chronic Lymphocytic Leukemia

Register for Updates

Learn More ›

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

NCT01188187

Completed

This Phase 3 study has been designed to confirm that adding custirsen to standard first-line docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard first-line docetaxel/prednisone treatment alone. This will be a randomized, open-label, multicenter, international trial. Treatment will consist of docetaxel/prednisone/custirsen vs. docetaxel/prednisone. A total of at least 1000 patients will be randomized. Patients will be randomly assigned with... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

10/13/2016

Locations: Teva Investigational Site 100, Birmingham, Alabama +139 locations

Teva Investigational Site 100, Birmingham, Alabama

Teva Investigational Site 086, Los Angeles, California

Teva Investigational Site 263, Los Angeles, California

Teva Investigational Site 093, Marina del Rey, California

Teva Investigational Site 097, San Diego, California

Teva Investigational Site 090, Fort Collins, Colorado

Teva Investigational Site 106, Fort Myers, Florida

Teva Investigational Site 094, Port St. Lucie, Florida

Teva Investigational Site 096, Atlanta, Georgia

Teva Investigational Site 103, Baton Rough, Louisiana

Teva Investigational Site 098, Ann Arbor, Michigan

Teva Investigational Site 112, Detroit, Michigan

Teva Investigational Site 032, Rochester, Minnesota

Teva Investigational Site 204, Las Vegas, Nevada

Teva Investigational Site 107, Cincinnati, Ohio

Teva Investigational Site 266, Greensboro, South Carolina

Teva Investigational Site 102, Myrtle Beach, South Carolina

Teva Investigational Site 084, Memphis, Tennessee

Teva Investigational Site 101, Nashville, Tennessee

Teva Investigational Site 116, San Antonio, Texas

Teva Investigational Site 059, Tyler, Texas

Teva Investigational Site 063, Tyler, Texas

Teva Investigational Site 047, Newport, Virginia

Teva Investigational Site 104, Norfolk, Virginia

Teva Investigational Site 029, Seattle, Washington

Teva Investigational Site 862, Bonheiden, Not set

Teva Investigational Site 860, Brussels, Not set

Teva Investigational Site 864, Edegem, Not set

Teva Investigational Site 863, Gent, Not set

Teva Investigational Site 002, Calgary, Alberta

Teva Investigational Site 023, Edmonton, Alberta

Teva Investigational Site 118, Abbotsford, British Columbia

Teva Investigational Site 007, Surrey, British Columbia

Teva Investigational Site 001, Vancouver, British Columbia

Teva Investigational Site 085, Victoria, British Columbia

Teva Investigational Site 024, Winnipeg, Manitoba

Teva Investigational Site 028, Halifax, Nova Scotia

Teva Investigational Site 025, Hamilton, Ontario

Teva Investigational Site 108, Kingston, Ontario

Teva Investigational Site 091, Oshawa, Ontario

Teva Investigational Site 003, Ottawa, Ontario

Teva Investigational Site 004, Toronto, Ontario

Teva Investigational Site 087, Toronto, Ontario

Teva Investigational Site 026, Montreal, Quebec

Teva Investigational Site 027, Montreal, Quebec

Teva Investigational Site 551, Angers Cedex 9, Not set

Teva Investigational Site 552, Avignon, Not set

Teva Investigational Site 553, Grenoble, Not set

Teva Investigational Site 555, La Roche-sur-Yon Cedex, Not set

Teva Investigational Site 557, Marseille, Not set

Teva Investigational Site 558, Nice Cedex 2, Not set

Teva Investigational Site 560, Paris Cedex 05, Not set

Teva Investigational Site 559, Paris Cedex 15, Not set

Teva Investigational Site 561, Saint Herblain Cedex, Not set

Teva Investigational Site 566, Saint-Brieuc Cedex, Not set

Teva Investigational Site 562, Saint-Priest-en-Jarez Cedex, Not set

Teva Investigational Site 563, Toulouse, Not set

Teva Investigational Site 564, Vandoeuvre-les-Nancy Cedex, Not set

Teva Investigational Site 550, Villejuif, Not set

Teva Investigational Site 607, Aachen, Not set

Teva Investigational Site 609, Berlin, Not set

Teva Investigational Site 613, Berlin, Not set

Teva Investigational Site 604, Darmstadt, Not set

Teva Investigational Site 612, Dresden, Not set

Teva Investigational Site 618, Greifswald, Not set

Teva Investigational Site 600, Hannover, Not set

Teva Investigational Site 606, Heidelberg, Not set

Teva Investigational Site 615, Heinsberg, Not set

Teva Investigational Site 611, Homburg/Saar, Not set

Teva Investigational Site 617, Kempen, Not set

Teva Investigational Site 608, Marburg, Not set

Teva Investigational Site 616, Meiningen, Not set

Teva Investigational Site 614, Muenchen, Not set

Teva Investigational Site 601, Muenster, Not set

Teva Investigational Site 602, Nuertingen, Not set

Teva Investigational Site 603, Stuttgart, Not set

Teva Investigational Site 610, Tuebingen, Not set

Teva Investigational Site 605, Wuppertal, Not set

Teva Investigational Site 691, Budapest, Not set

Teva Investigational Site 694, Budapest, Not set

Teva Investigational Site 692, Debrecen, Not set

Teva Investigational Site 697, Debrecen, Not set

Teva Investigational Site 696, Gyor, Not set

Teva Investigational Site 698, Miskolc, Not set

Teva Investigational Site 699, Nyiregyhaza, Not set

Teva Investigational Site 693, Szeged, Not set

Teva Investigational Site 695, Veszprem, Not set

Teva Investigational Site 506, Jerusalem, IL

Teva Investigational Site 507, Haifa, Not set

Teva Investigational Site 505, Petach Tikva, Not set

Teva Investigational Site 502, Ramat Gan, Not set

Teva Investigational Site 503, Tel Aviv, Not set

Teva Investigational Site 501, Zrifin, Not set

Teva Investigational Site 753, Arezzo, Not set

Teva Investigational Site 758, Catanzaro, Not set

Teva Investigational Site 760, Cesena (FC), Not set

Teva Investigational Site 752, Genova, Not set

Teva Investigational Site 755, Lugo (Ravenna), Not set

Teva Investigational Site 759, Meldola (FC), Not set

Teva Investigational Site 763, Milano, Not set

Teva Investigational Site 754, Napoli, Not set

Teva Investigational Site 756, Napoli, Not set

Teva Investigational Site 761, Rimini, Not set

Teva Investigational Site 750, Roma, Not set

Teva Investigational Site 762, Roma, Not set

Teva Investigational Site 764, Rozzano (MI), Not set

Teva Investigational Site 765, Verona, Not set

Teva Investigational Site 404, Cheongju,Chungbuk, Not set

Teva Investigational Site 401, Goyang-si Gyeonggi-do, Not set

Teva Investigational Site 400, Seoul, Not set

Teva Investigational Site 402, Seoul, Not set

Teva Investigational Site 403, Seoul, Not set

Teva Investigational Site 406, Seoul, Not set

Teva Investigational Site 405, Yangsan-si, Not set

Teva Investigational Site 851, Amsterdam, Not set

Teva Investigational Site 852, Rotterdam, Not set

Teva Investigational Site 853, Sittard-Geleen, Not set

Teva Investigational Site 803, Barcelona, Not set

Teva Investigational Site 808, Barcelona, Not set

Teva Investigational Site 809, Barcelona, Not set

Teva Investigational Site 816, Dos Hermanas, Not set

Teva Investigational Site 814, El Palmar, Not set

Teva Investigational Site 807, Guadalajara, Not set

Teva Investigational Site 800, Madrid, Not set

Teva Investigational Site 801, Madrid, Not set

Teva Investigational Site 806, Madrid, Not set

Teva Investigational Site 813, Madrid, Not set

Teva Investigational Site 815, Manresa, Not set

Teva Investigational Site 810, Murcia, Not set

Teva Investigational Site 811, Palma de Mallorca, Not set

Teva Investigational Site 805, Pamplona, Not set

Teva Investigational Site 804, Sabadell - Barcelona, Not set

Teva Investigational Site 802, Valencia, Not set

Teva Investigational Site 704, Brighton, Not set

Teva Investigational Site 701, Cambridge, Not set

Teva Investigational Site 709, Coventry, Not set

Teva Investigational Site 705, Guildford, Surrey, Not set

Teva Investigational Site 703, Manchester, Not set

Teva Investigational Site 700, Surrey, Not set

Teva Investigational Site 710, Wirral, Not set

Conditions: Prostate Cancer

Register for Updates

Learn More ›

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)

NCT01396083

Completed

This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/21/2016

Locations: Novartis Investigative Site, Augsburg, Not set +63 locations

Novartis Investigative Site, Augsburg, Not set

Novartis Investigative Site, Bad Rothenfelde, Not set

Novartis Investigative Site, Berlin, Not set

Novartis Investigative Site, Bonn, Not set

Novartis Investigative Site, Bremen, Not set

Novartis Investigative Site, Chemnitz, Not set

Novartis Investigative Site, Darmstadt, Not set

Novartis Investigative Site, Dortmund, Not set

Novartis Investigative Site, Dresden, Not set

Novartis Investigative Site, Duesseldorf, Not set

Novartis Investigative Site, Frankfurt, Not set

Novartis Investigative Site, Freiburg i. Br, Not set

Novartis Investigative Site, Glauchau, Not set

Novartis Investigative Site, Göttingen, Not set

Novartis Investigative Site, Hagen, Not set

Novartis Investigative Site, Hamburg, Not set

Novartis Investigative Site, Homburg, Not set

Novartis Investigative Site, Ingolstadt, Not set

Novartis Investigative Site, Karlsruhe, Not set

Novartis Investigative Site, Kiel, Not set

Novartis Investigative Site, Koeln, Not set

Novartis Investigative Site, Lauterbach, Not set

Novartis Investigative Site, Leipzig, Not set

Novartis Investigative Site, Ludwigshafen, Not set

Novartis Investigative Site, Minden, Not set

Novartis Investigative Site, Muelheim, Not set

Novartis Investigative Site, Muenster, Not set

Novartis Investigative Site, München, Not set

Novartis Investigative Site, Nuernberg, Not set

Novartis Investigative Site, Recklinghausen, Not set

Novartis Investigative Site, Regensburg, Not set

Novartis Investigative Site, Sulzbach, Not set

Novartis Investigative Site, Tübingen, Not set

Novartis Investigative Site, Ulm, Not set

Novartis Investigative Site, Wolfsburg, Not set

Novartis Investigative Site, Würzburg, Not set

Novartis Investigative Site, Budapest, Not set

Novartis Investigative Site, Szeged, Not set

Novartis Investigative Site, Bydgoszcz, Not set

Novartis Investigative Site, Bytom, Not set

Novartis Investigative Site, Birmingham, Not set

Novartis Investigative Site, Bradford, Not set

Novartis Investigative Site, Cheshire, Not set

Novartis Investigative Site, Colchester, Not set

Novartis Investigative Site, Derby, Not set

Novartis Investigative Site, Gloucester, Not set

Novartis Investigative Site, Guildford, Surrey, Not set

Novartis Investigative Site, Kent, Not set

Novartis Investigative Site, Leeds, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Manchester, Not set

Novartis Investigative Site, Middlesborough, Not set

Novartis Investigative Site, Nottingham, Not set

Novartis Investigative Site, Portsmouth, Not set

Novartis Investigative Site, Rugby, Not set

Novartis Investigative Site, Westcliff-on-Sea, Not set

Novartis Investigative Site, York, Not set

Conditions: Visual Impairment, Macular Edema, Central Retinal Vein Occlusion

Register for Updates

Learn More ›

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

NCT00532155

Completed

The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunog... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/04/2016

Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey +31 locations

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey

Sanofi-Aventis Administrative Office, Buenos Aires, Not set

sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales

Sanofi-Aventis Administrative Office, Wien, Not set

Sanofi-Aventis Administrative Office, Sao Paulo, Not set

Sanofi-Aventis Administrative Office, Sofia, Not set

Sanofi-Aventis Administrative Office, Laval, Not set

Sanofi-Aventis Administrative Office, Santiago, Not set

Sanofi-Aventis Administrative Office, Shangai, Not set

Sanofi-Aventis Administrative Office, Praha, Not set

Sanofi-Aventis Administrative Office, Tallinn, Not set

Sanofi-Aventis Administrative Office, Helsinki, Not set

Sanofi-Aventis Administrative Office, Paris, Not set

Sanofi-Aventis Administrative Office, Berlin, Not set

Sanofi-Aventis Administrative Office, Athens, Not set

Sanofi-Aventis Administrative Office, Causeway Bay, Not set

Sanofi-Aventis Administrative Office, Budapest, Not set

Sanofi-Aventis Administrative Office, Mumbai, Not set

Sanofi-Aventis Administrative Office, Milano, Not set

Sanofi-Aventis Administrative Office, Seoul, Not set

Sanofi-Aventis Administrative Office, Kuala Lumpur, Not set

Sanofi-Aventis Administrative Office, Gouda, Not set

Sanofi-Aventis Administrative Office, Warszawa, Not set

Sanofi-Aventis Administrative Office, Porto Salvo, Not set

Sanofi-Aventis Administrative Office, Bucuresti, Not set

Sanofi-Aventis Administrative Office, Moscow, Not set

Sanofi-Aventis Administrative Office, Singapore, Not set

Sanofi-Aventis Administrative Office, Barcelona, Not set

Sanofi-Aventis Administrative Office, Bromma, Not set

Sanofi-Aventis Administrative Office, Taipei, Not set

Sanofi-Aventis Administraive Office, Istanbul, Not set

Sanofi-Aventis Admnistrative Office, Guildford Surrey, Not set

Conditions: Carcinoma, Non Small Cell Lung

Register for Updates

Learn More ›

A Long-Term Safety Study of OZURDEX® in Clinical Practice

NCT01539577

Completed

This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or patients with non-infectious posterior segment uveitis in real-world clinical practice.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/18/2016

Locations: Not set, Paris, Not set +3 locations

Conditions: Retinal Vein Occlusion, Macular Edema, Uveitis, Posterior

Register for Updates

Learn More ›

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

NCT00317408

Unknown

RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune system from rejecting the stem cells. When the stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy and total-body irradiation followed by a stem... Read More

Gender:

ALL

Ages:

21 years and below

Trial Updated:

09/24/2015

Locations: St. Anna Children's Hospital, Vienna, Not set +97 locations

St. Anna Children's Hospital, Vienna, Not set

U.Z. Gasthuisberg, Leuven, Not set

University Hospital Brno, Brno, Not set

Charles University Hospital, Prague 5, Not set

Centre Leon Berard, Lyon, Not set

Kinderklinik - Universitaetsklinikum Aachen, Aachen, Not set

Klinikum Augsburg, Augsburg, Not set

Helios Klinikum Berlin, Berlin, Not set

Charite University Hospital - Campus Virchow Klinikum, Berlin, Not set

Evangelisches Krankenhauus Bielfeld, Biefeld, Not set

Kinderklinik der Universitaet Bonn, Bonn, Not set

Staedtisches Klinikum - Howedestrase, Braunschweig, Not set

Klinikum Bremen-Mitte, Bremen, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Not set

Children's Hospital, Cologne, Not set

Carl - Thiem - Klinkum Cottbus, Cottbus, Not set

Vestische Kinderklinik, Datteln, Not set

Klinikum Dortmund, Dortmund, Not set

Universitatsklinikum Carl Gustav Carus, Dresden, Not set

Universitaetsklinikum Duesseldorf, Duesseldorf, Not set

Helios Klinikum Erfurt, Erfurt, Not set

Universitaets - Kinderklinik, Erlangen, Not set

Universitaetsklinikum Essen, Essen, Not set

Klinikum der J.W. Goethe Universitaet, Frankfurt, Not set

Universitaetskinderklinik - Universitaetsklinikum Freiburg, Freiburg, Not set

Kinderklinik, Giessen, Not set

Universitaetsklinikum Goettingen, Goettingen, Not set

Klinik und Poliklinik Fuer Kinder-und Jugendmedizin - Universitaetsklinikum Greifswald, Greifswald, Not set

University Medical Center Hamburg - Eppendorf, Hamburg, Not set

Medizinische Hochschule Hannover, Hannover, Not set

Universitaets-Kinderklinik Heidelberg, Heidelberg, Not set

Gemeinschaftskrankenhaus, Herdecke, Not set

Universitaetsklinikum des Saarlandes, Homburg, Not set

Universitaets - Kinderklinik, Jena, Not set

Staedtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Not set

Klinikum Kassel, Kassel, Not set

University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Not set

Klinikum Kemperhof Koblenz, Koblenz, Not set

Klinikum Krefeld GmbH, Krefeld, Not set

Universitaets - Kinderklinik, Leipzig, Not set

St. Annastift Krankenhaus, Ludwigshafen, Not set

Universitaets - Kinderklinik - Luebeck, Luebeck, Not set

Universitatsklinikum der MA, Magdeburg, Not set

Johannes Gutenberg University, Mainz, Not set

Staedtisches Klinik - Kinderklinik, Mannheim, Not set

Universitaets - Kinderklinik, Marburg, Not set

Klinikum Minden, Minden, Not set

Klinik und Poliklinik fuer Kinder und Jugendmedizin - Universitaetsklinikum Muenster, Muenster, Not set

Krankenhaus Muenchen Schwabing, Munich, Not set

Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Not set

Kinderklinik Kohlhof, Neunkirchen, Not set

Cnopf'sche Kinderklinik, Nuremberg, Not set

Klinikum Oldenburg, Oldenburg, Not set

Klinik St. Hedwig-Kinderklinik, Regensburg, Not set

Kinderklinik - Universitaetsklinikum Rostock, Rostock, Not set

Saarbrucker Winterbergkliniken, Saarbrucken, Not set

Klinikum Schwerin, Schwerin, Not set

Kinderklink Siegen Deutsches Rotes Kreuz, Siegen, Not set

Johanniter-Kinderklinik, St. Augustin, Not set

Olgahospital, Stuttgart, Not set

Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Not set

Universitaetsklinikum Tuebingen, Tuebingen, Not set

Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm, Not set

Dr. Horst-Schmidt-Kliniken, Wiesbaden, Not set

Universitaets - Kinderklinik Wuerzburg, Wuerzburg, Not set

Helios Kliniken Wuppertal University Hospital, Wuppertal, Not set

Our Lady's Hospital for Sick Children Crumlin, Dublin, Not set

Azienda Ospedaliera di Padova, Padova, Not set

Erasmus MC - Sophia Children's Hospital, Rotterdam, Not set

Akademia Medyczna im. Piastow Slaskich, Wroclaw, Not set

Goeteborg University, Goeteborg, Not set

Kantonspital Aarau, Aarau, Not set

Universitaets-Kinderspital beider Basel, Basel, Not set

Ospedale "la Carita", Locarno, Locarno, Not set

Kinderspital Luzern, Lucerne 16, Not set

Ostschweizer Kinderspital, St. Gallen, Not set

University Children's Hospital, Zurich, Not set

Birmingham Children's Hospital, Birmingham, England

Institute of Child Health at University of Bristol, Bristol, England

Addenbrooke's Hospital, Cambridge, England

Leeds Cancer Centre at St. James's University Hospital, Leeds, England

Leicester Royal Infirmary, Leicester, England

Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England

Middlesex Hospital, London, England

Great Ormond Street Hospital for Children, London, England

Royal Manchester Children's Hospital, Manchester, England

Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England

Queen's Medical Centre, Nottingham, England

Oxford Radcliffe Hospital, Oxford, England

Children's Hospital - Sheffield, Sheffield, England

Southampton General Hospital, Southampton, England

Royal Marsden - Surrey, Sutton, England

Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland

Royal Aberdeen Children's Hospital, Aberdeen, Scotland

Royal Hospital for Sick Children, Edinburgh, Scotland

Royal Hospital for Sick Children, Glasgow, Scotland

Childrens Hospital for Wales, Cardiff, Wales

Conditions: Lymphoma

Register for Updates

Learn More ›

Dexamethasone Treatment Options in United Kingdom

Match to Clinical Trials